I think the answer to this question has a few answers: 1) completely novel class with no precedent as opposed to the nucleoside analogs etc 2) High monetary stakes to big pharma ie even though the success of Rems is moderate at best, they have the power to continue to benefit 3) we are small....we need just stellar clinical results to overcome this.

Brilacidin makes so much sense from an immunologic and biochemical standpoint...in a few years it will be thought of as THE one that started a revolution. Degrado and others at UCSF and UW are on the cutting edge. Think about the discoverer of ivermectin. He won the Nobel. What will happen with Degrado and his former UPenn colleagues. He joined, he is excited. If he is excited, I am too